NuVasive, Inc. (NASDAQ:NUVA) issued an update on its FY17 earnings guidance on Tuesday morning. The company provided EPS guidance of $1.91 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.99. The company issued revenue guidance of $1.030 billion, compared to the consensus revenue estimate of $1.09 billion.

NuVasive, Inc. (NASDAQ:NUVA) traded down 0.69% during mid-day trading on Tuesday, hitting $54.59. 2,037,550 shares of the stock were exchanged. The firm has a 50-day moving average price of $55.81 and a 200-day moving average price of $68.45. NuVasive, Inc. has a 12-month low of $49.25 and a 12-month high of $81.68. The stock has a market capitalization of $2.77 billion, a P/E ratio of 85.97 and a beta of 1.04.

NuVasive (NASDAQ:NUVA) last issued its quarterly earnings data on Thursday, July 27th. The medical device company reported $0.46 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.02. NuVasive had a return on equity of 13.04% and a net margin of 3.50%. The business had revenue of $260.60 million during the quarter, compared to analyst estimates of $261.95 million. During the same period in the previous year, the firm earned $0.40 EPS. NuVasive’s quarterly revenue was up 10.3% compared to the same quarter last year. Equities analysts predict that NuVasive, Inc. will post $1.99 earnings per share for the current fiscal year.

Several research firms have commented on NUVA. TheStreet cut NuVasive from a b- rating to a c+ rating in a research note on Friday, October 13th. Barclays PLC cut their target price on NuVasive from $80.00 to $65.00 and set an overweight rating on the stock in a research note on Thursday, October 19th. Gabelli restated a buy rating on shares of NuVasive in a research note on Monday, July 31st. BidaskClub cut NuVasive from a buy rating to a hold rating in a research note on Monday, July 31st. Finally, Needham & Company LLC restated a hold rating on shares of NuVasive in a research note on Friday, July 28th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $74.62.

In other news, CEO Gregory T. Lucier acquired 5,000 shares of the firm’s stock in a transaction on Thursday, August 17th. The shares were purchased at an average cost of $66.22 per share, with a total value of $331,100.00. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, EVP Peter Michael Leddy acquired 7,850 shares of the firm’s stock in a transaction on Tuesday, August 1st. The stock was purchased at an average cost of $63.88 per share, for a total transaction of $501,458.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 14,850 shares of company stock worth $955,598 over the last three months. 1.20% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: “NuVasive, Inc. (NUVA) Issues FY17 Earnings Guidance” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at

NuVasive Company Profile

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Earnings History and Estimates for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with's FREE daily email newsletter.